Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease

NCT00072943 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00072943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease
Lead sponsor
Facet Biotech
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2002
Completion date
April 30, 2004
Enrollment
175
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, crohn's disease, digestive system disease, gastrointestinal disease, intestinal disease